up-to-date with a click!
Update July, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications July 2017

Other

  1. Huesch MD. Commercial Online Social Network Data and Statin Side-Effect Surveillance: A Pilot Observational Study of Aggregate Mentions on Facebook. Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28748367
  2. Oommen AM, Nand K, Abraham VJ et al. Prevalence of statin use among high-risk patients in urban and rural Vellore, Tamil Nadu: A population-based cross-sectional study. Indian journal of pharmacology 2017; 49:201-204. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706335
  3. Obonska K, Kasprzak M, Sikora J et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials 2017; 18:316. http://www.ncbi.nlm.nih.gov/pubmed/?term=28697767

Add on treatments

  1. El Shahawy M, Cannon CP, Blom DJ et al. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750828
  2. Ke X, Ke B, Wang X et al. Additive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot study. Archives of medical science : AMS 2017; 13:956-961. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721163
  3. Stulc T, Lanska V, Snejdrlova M et al. A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. Archives of medical science : AMS 2017; 13:705-710. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721135
  4. Ghanim H, Green K, Abuaysheh S et al. Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. Atherosclerosis 2017; 263:278-286. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711708
  5. Capogrosso Sansone A, Convertino I, Galiulo MT et al. Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database. Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28681266
  6. Almalki ZS, Guo JJ, Alahmari A et al. Cost-effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients with a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. Heart, lung & circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716519
  7. Calza L, Magistrelli E, Colangeli V et al. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infectious diseases (London, England) 2017:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28683645
  8. Sharma N, Cooper R, Kuh D. Associations of statin use with motor performance and myalgia may be modified by 25-hydroxyvitamin D: findings from a British birth cohort. Scientific reports 2017; 7:6578. http://www.ncbi.nlm.nih.gov/pubmed/?term=28747665
  9. Obonska K, Kasprzak M, Sikora J et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials 2017; 18:316. http://www.ncbi.nlm.nih.gov/pubmed/?term=28697767

Adherence

  1. Tanner RM, Safford MM, Monda KL et al. Primary Care Physician Perspectives on Barriers to Statin Treatment. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28710589
  2. Ennezat PV, Guerbaai RA. Real Clinical Significance of Statin Cessation After Adjustment for Smoking Persistence and Antiplatelet Treatment Discontinuation. J Am Coll Cardiol 2017; 70:684-685. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750706
  3. Serban MC, Muntner P, Rosenson RS. Reply: Statin Intolerance and Risk for Recurrent Myocardial Infarction, Coronary Heart Disease Events, and All-Cause Mortality. J Am Coll Cardiol 2017; 70:685-686. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750708
  4. Raebel MA, Dyer W, Nichols GA et al. Relationships Between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients With Diabetes. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28752555

Atherosclerosis & Imaging

  1. Kabaklic A, Fras Z. Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram: a pilot study. Archives of medical science : AMS 2017; 13:827-836. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721151
  2. Shah Z, Masoomi R, Thapa R et al. Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study. Cerebrovasc Dis 2017; 44:150-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689200
  3. Kwon O, Kang SJ, Kang SH et al. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679524
  4. Taqueti VR, Ridker PM. Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy: More Than Meets the Plaque. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679526
  5. Zhang L, Wahle A, Chen Z et al. Predicting Locations of High-Risk Plaques in Coronary Arteries in Patients Receiving Statin Therapy. IEEE transactions on medical imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28708548
  6. Briguori C, Quintavalle C, D'Alessio F et al. Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28668399
  7. Chen W, Tian T, Wang S et al. The characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course and the intervention by statins in the very elderly patients. Journal of diabetes investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685957
  8. Im E, Cho YH, Suh Y et al. High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716428
  9. Murin J. [What has the GLAGOV clinical study shown?]. Vnitr Lek 2017; 63:329-332. http://www.ncbi.nlm.nih.gov/pubmed/?term=28726431

Atorvastatin/Rosuvastatin

  1. Kabaklic A, Fras Z. Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram: a pilot study. Archives of medical science : AMS 2017; 13:827-836. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721151
  2. Ke X, Ke B, Wang X et al. Additive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot study. Archives of medical science : AMS 2017; 13:956-961. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721163
  3. Kaviani E, Rahmani M, Kaeidi A et al. Protective Effect of Atorvastatin on D-galactose-Induced Aging Model in Mice. Behavioural brain research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750834
  4. Aouba A. KRASG12D, pulmonary LCH, and atorvastatin. Blood 2017; 130:391-392. http://www.ncbi.nlm.nih.gov/pubmed/?term=28751357
  5. Loch A, Bewersdorf JP, Kofink D et al. Generic atorvastatin is as effective as the brand-name drug (LIPITOR(R)) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC research notes 2017; 10:291. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716156
  6. Awad K, Mikhailidis DP, Toth PP et al. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28741244
  7. Kwon O, Kang SJ, Kang SH et al. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679524
  8. Taqueti VR, Ridker PM. Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy: More Than Meets the Plaque. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679526
  9. Koh KK. Letter by Koh Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". Circulation 2017; 136:118-119. http://www.ncbi.nlm.nih.gov/pubmed/?term=28674099
  10. Watts GF, Chan DC, Somaratne R et al. Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". Circulation 2017; 136:120-121. http://www.ncbi.nlm.nih.gov/pubmed/?term=28674100
  11. Mitsiou E, Boutari C, Kotsis V et al. Effect of low (5 mg) vs high (20-40 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28669329
  12. Xie Y, Tan X, Huang J et al. Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis. Drug delivery 2017; 24:1067-1076. http://www.ncbi.nlm.nih.gov/pubmed/?term=28705021
  13. Han E, Kim G, Lee JY et al. Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes. Endocrinol Metab (Seoul) 2017; 32:274-280. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685516
  14. Stopfer P, Giessmann T, Hohl K et al. Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. European journal of drug metabolism and pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685495
  15. Chen L, Cai P, Cheng Z et al. Pharmacological postconditioning with atorvastatin calcium attenuates myocardial ischemia/reperfusion injury in diabetic rats by phosphorylating GSK3beta. Experimental and therapeutic medicine 2017; 14:25-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672889
  16. Wang Y, Geng Y, Shi Z et al. Good recovery of subarachnoid hemorrhage concomitant with ischemia due to anterior cerebral artery dissection by conservative treatment: A case report. Experimental and therapeutic medicine 2017; 14:155-158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672907
  17. Manoj K, Jain N, Madhu SV. Myopathy in Patients Taking Atorvastatin: A Pilot Study. Indian journal of endocrinology and metabolism 2017; 21:504-509. http://www.ncbi.nlm.nih.gov/pubmed/?term=28670530
  18. Calza L, Magistrelli E, Colangeli V et al. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infectious diseases (London, England) 2017:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28683645
  19. Briguori C, Quintavalle C, D'Alessio F et al. Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28668399
  20. Foley R, Singh GD, Kokkinidis DG et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711864
  21. Lawler PR, Akinkuolie AO, Chu AY et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28733430
  22. Khan TM, Iqbal S, Rashid MA. Comparison Of Lipid Lowering Effect Of Extra Virgin Olive Oil And Atorvastatin In Dyslipidaemia In Type 2 Diabetes Mellitus. Journal of Ayub Medical College, Abbottabad : JAMC 2017; 29:83-86. http://www.ncbi.nlm.nih.gov/pubmed/?term=28712181
  23. Selim A, Khalaf MM, Gad AM, Abd El-Raouf OM. Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin-induced renal injury in rats. Journal of biochemical and molecular toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28683192
  24. Farzanegan GR, Derakhshan N, Khalili H et al. Effects of atorvastatin on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury; a randomized double-blind placebo-controlled clinical trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28688622
  25. Chen W, Tian T, Wang S et al. The characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course and the intervention by statins in the very elderly patients. Journal of diabetes investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685957
  26. Buttar RS, Batra J, Kreimerman J et al. Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels. Journal of general internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28707259
  27. Al-Kuraishy HM, Al-Gareeb AI. Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins. Journal of laboratory physicians 2017; 9:163-169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706385
  28. Syed MH, Khandelwal PN, Thawani VR, Katare SS. Efficacy of Atorvastatin in Prevention of Contrast-induced Nephropathy in High-risk Patients Undergoing Angiography: A Double-blind Randomized Controlled Trial. Journal of pharmacology & pharmacotherapeutics 2017; 8:50-53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706398
  29. Wander GS, Jadhav UM, Chemburkar A et al. Lipid management in India: a nationwide, cross-sectional physician survey. Lipids Health Dis 2017; 16:130. http://www.ncbi.nlm.nih.gov/pubmed/?term=28673294
  30. Bei WJ, Chen SQ, Li HL et al. Comparing common doses (double-dose vs usual-dose) of atorvastatin for preventing contrast-induced acute kidney injury and mortality after coronary angiography. Medicine (Baltimore) 2017; 96:e7501. http://www.ncbi.nlm.nih.gov/pubmed/?term=28746193
  31. Liang M, Yang S, Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials. Medicine (Baltimore) 2017; 96:e7384. http://www.ncbi.nlm.nih.gov/pubmed/?term=28682890
  32. Knapik-Kowalczuk J, Wojnarowska Z, Rams-Baron M et al. Atorvastatin as a promising crystallization inhibitor of amorphous probucol. Dielectric studies at ambient and elevated pressure. Molecular pharmaceutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28692796
  33. Sun T, Zhang HJ, Krittanawong C et al. Acute atorvastatin treatment restores the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28732362
  34. Carillion A, Feldman S, Na N et al. Atorvastatin reduces beta-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS One 2017; 12:e0180103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28727746
  35. Leite GAA, Figueiredo TM, Sanabria M et al. Ascorbic acid supplementation partially prevents the delayed reproductive development in juvenile male rats exposed to rosuvastatin since prepuberty. Reproductive toxicology (Elmsford, N.Y.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28729172
  36. Naeimi RA, Amiri FT, Khalatbary AR et al. Atorvastatin mitigates testicular injuries induced by ionizing radiation in mice. Reproductive toxicology (Elmsford, N.Y.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28668617
  37. Im E, Cho YH, Suh Y et al. High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716428
  38. Obonska K, Kasprzak M, Sikora J et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials 2017; 18:316. http://www.ncbi.nlm.nih.gov/pubmed/?term=28697767
  39. Murin J. [What has the GLAGOV clinical study shown?]. Vnitr Lek 2017; 63:329-332. http://www.ncbi.nlm.nih.gov/pubmed/?term=28726431
  40. Shin SK, Cho JH, Kim EJ et al. Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model. World J Gastroenterol 2017; 23:4559-4568. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740344
  41. Navratilova L, Mandikova JR, Pavek P et al. Honey flavonoids inhibit hOATP2B1 and hOATP1A2 transporters and hOATP-mediated rosuvastatin cell uptake in vitro. Xenobiotica 2017:1-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=28745105 

Basic science

  1. Ke X, Ke B, Wang X et al. Additive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot study. Archives of medical science : AMS 2017; 13:956-961. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721163
  2. Kaviani E, Rahmani M, Kaeidi A et al. Protective Effect of Atorvastatin on D-galactose-Induced Aging Model in Mice. Behavioural brain research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750834
  3. Mathew LE, Rajagopal V, A H. Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 93:681-694. http://www.ncbi.nlm.nih.gov/pubmed/?term=28692940
  4. Aouba A. KRASG12D, pulmonary LCH, and atorvastatin. Blood 2017; 130:391-392. http://www.ncbi.nlm.nih.gov/pubmed/?term=28751357
  5. Eilenberg W, Stojkovic S, Kaider A et al. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672747
  6. Qiao F, Zhang J, Wang J et al. Silk fibroin-coated PLGA dimpled microspheres for retarded release of simvastatin. Colloids and surfaces. B, Biointerfaces 2017; 158:112-118. http://www.ncbi.nlm.nih.gov/pubmed/?term=28686902
  7. Xie Y, Tan X, Huang J et al. Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis. Drug delivery 2017; 24:1067-1076. http://www.ncbi.nlm.nih.gov/pubmed/?term=28705021
  8. Ghayour MB, Abdolmaleki A, Rassouli MB. Neuroprotective effect of Lovastatin on motor deficit induced by sciatic nerve crush in the rat. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28688913
  9. Groeneveld ME, van der Reijden JJ, Tangelder GJ et al. Peroxynitrite Footprint in Circulating Neutrophils of Abdominal Aortic Aneurysm Patients Is Lower in Statin than in Non-statin Users. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28712812
  10. Mao Y, Koga JI, Tokutome M et al. Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Left Ventricular Remodeling After Acute Myocardial Infarction by Inhibiting Monocyte-Mediated Inflammation. Int Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28701679
  11. Yang H, Huang F, Tao Y et al. Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in mice. International journal of molecular medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28677744
  12. Gehrke T, Scherzad A, Hackenberg S et al. Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro. International journal of oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28713941
  13. El-Zaher AA, Elkady EF, Elwy HM, Saleh M. A Versatile Liquid Chromatographic Method for the Simultaneous Determination of Metformin, Sitagliptin, Simvastatin, and Ezetimibe in Different Dosage Forms. J AOAC Int 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28748781
  14. Selim A, Khalaf MM, Gad AM, Abd El-Raouf OM. Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin-induced renal injury in rats. Journal of biochemical and molecular toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28683192
  15. Alaarg A, Senders ML, Varela-Moreira A et al. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J Control Release 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28700897
  16. Al-Kuraishy HM, Al-Gareeb AI. Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins. Journal of laboratory physicians 2017; 9:163-169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706385
  17. Saifi AM, Giraddi GB, Ahmed N. Healing of extraction socket following local application of simvastatin: A split mouth prospective study. Journal of oral biology and craniofacial research 2017; 7:106-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706784
  18. Devalapalli MMR, Cheruvu HS, Yertha T et al. Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry. Journal of separation science 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28722356
  19. Cunha V, Santos MM, Moradas-Ferreira P et al. Simvastatin modulates gene expression of key receptors in zebrafish embryos. Journal of toxicology and environmental health. Part A 2017:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28682217
  20. Obayashi H, Kobayashi N, Nezu Y et al. Plasma 2-hydroxyglutarate and hexanoylcarnitine levels are potential biomarkers for skeletal muscle toxicity in male Fischer 344 rats. The Journal of toxicological sciences 2017; 42:385-396. http://www.ncbi.nlm.nih.gov/pubmed/?term=28717097
  21. Sequetto PL, Goncalves RV, Pinto AS et al. Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28743325
  22. Knapik-Kowalczuk J, Wojnarowska Z, Rams-Baron M et al. Atorvastatin as a promising crystallization inhibitor of amorphous probucol. Dielectric studies at ambient and elevated pressure. Molecular pharmaceutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28692796
  23. Sun T, Zhang HJ, Krittanawong C et al. Acute atorvastatin treatment restores the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28732362
  24. Pu H, Zhang Q, Zhao C et al. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer. Pathology oncology research : POR 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28744693
  25. Kriegbaum M, Liisberg KB, Wallach-Kildemoes H. Pattern of statin use changes following media coverage of its side effects. Patient preference and adherence 2017; 11:1151-1157. http://www.ncbi.nlm.nih.gov/pubmed/?term=28744105
  26. Jia S, Xie P, Hong SJ et al. Local Application of Statins Significantly Reduced Hypertrophic Scarring in a Rabbit Ear Model. Plastic and reconstructive surgery. Global open 2017; 5:e1294. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740761
  27. Carillion A, Feldman S, Na N et al. Atorvastatin reduces beta-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS One 2017; 12:e0180103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28727746
  28. Sun X, Mathew B, Sammani S et al. Simvastatin-induced sphingosine 1-phosphate receptor 1 expression is KLF2-dependent in human lung endothelial cells. Pulmonary circulation 2017; 7:117-125. http://www.ncbi.nlm.nih.gov/pubmed/?term=28680571
  29. Leite GAA, Figueiredo TM, Sanabria M et al. Ascorbic acid supplementation partially prevents the delayed reproductive development in juvenile male rats exposed to rosuvastatin since prepuberty. Reproductive toxicology (Elmsford, N.Y.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28729172
  30. de Wolf E, Abdullah MI, Jones SM et al. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Scientific reports 2017; 7:5410. http://www.ncbi.nlm.nih.gov/pubmed/?term=28710496
  31. Wu S, Yang R, Wang G. Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4+ CD25+ Foxp3+ T cells in an asthma mouse model. Scientific reports 2017; 7:6084. http://www.ncbi.nlm.nih.gov/pubmed/?term=28729731
  32. Perini M, Carbone G, Camin F. Stable isotope ratio analysis for authentication of red yeast rice. Talanta 2017; 174:228-233. http://www.ncbi.nlm.nih.gov/pubmed/?term=28738573
  33. Sonvico F, Zimetti F, Pohlmann AR, Guterres SS. Drug delivery to the brain: how can nanoencapsulated statins be used in the clinic? Therapeutic delivery 2017; 8:625-631. http://www.ncbi.nlm.nih.gov/pubmed/?term=28730939
  34. Shin SK, Cho JH, Kim EJ et al. Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model. World J Gastroenterol 2017; 23:4559-4568. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740344
  35. Mauro M, Lepera JS, Borsari B et al. Effect of inhalation exposure to toluene on the activity of organic anion transporting polypeptide (Oatp) using pravastatin as a probe drug in rats. Xenobiotica 2017:1-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=28686078
  36. Tan LC, Zhao L, Liu XH et al. [Antagonism of lovastatin on oxidative stress and apoptosis in primary rat hippocampal neurons induced by beta-amyloid peptide]. Zhonghua bing li xue za zhi = Chinese journal of pathology 2017; 46:491-496. http://www.ncbi.nlm.nih.gov/pubmed/?term=28728224 

Cancer

  1. Smith A, Murphy L, Zgaga L et al. Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer. Br J Cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28720842
  2. Gehrke T, Scherzad A, Hackenberg S et al. Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro. International journal of oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28713941
  3. Pursnani A, Massaro JM, D'Agostino RB, Sr. et al. Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017:Jco2016713594. http://www.ncbi.nlm.nih.gov/pubmed/?term=28700275
  4. Thomas T, Loke Y, Beales ILP. Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma. Journal of gastrointestinal cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28691139
  5. Xie W, Zhu Q, Liu Q et al. Statin use and endometrial cancer risk: a meta-analysis. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711915
  6. de Wolf E, Abdullah MI, Jones SM et al. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Scientific reports 2017; 7:5410. http://www.ncbi.nlm.nih.gov/pubmed/?term=28710496

Children

  1. Lasam G, Shambhu S, Fishberg R. Heterozygous Familial Hypercholesterolemia With APOE Haplotype: A Prospective Harbinger of a Catastrophic Cardiovascular Event. Cardiology research 2017; 8:117-122. http://www.ncbi.nlm.nih.gov/pubmed/?term=28725328
  2. Vuorio A, Kuoppala J, Kovanen PT et al. Statins for children with familial hypercholesterolemia. The Cochrane database of systematic reviews 2017; 7:Cd006401. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685504

Cost-effectiveness

  1. Mortensen MB, Falk E, Schmidt M. Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28698192
  2. Heller DJ, Coxson PG, Penko J et al. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28687710
  3. Almalki ZS, Guo JJ, Alahmari A et al. Cost-effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients with a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. Heart, lung & circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716519

CVD

  1. Tentzeris I, Farhan S, Freynhofer MK et al. Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28734463
  2. Oza A, Lu N, Schoenfeld SR et al. Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28698231
  3. Vlachopoulos C, Andrikopoulos G, Terentes-Printzios D et al. Patients with acute coronary syndrome are at high risk prior to the event and lipid management is underachieved pre- and post-hospitalization. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676022
  4. Park CH, Kang EW, Park JT et al. Association of serum lipid levels over time with survival in incident peritoneal dialysis patients. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28669685
  5. Pursnani A, Massaro JM, D'Agostino RB, Sr. et al. Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017:Jco2016713594. http://www.ncbi.nlm.nih.gov/pubmed/?term=28700275
  6. Sun T, Zhang HJ, Krittanawong C et al. Acute atorvastatin treatment restores the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28732362
  7. Kim SW, Kang HJ, Bae KY et al. Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. Progress in neuro-psychopharmacology & biological psychiatry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689006
  8. Im E, Cho YH, Suh Y et al. High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716428

Endothelium/inflammation

  1. Kwon O, Kang SJ, Kang SH et al. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679524
  2. Taqueti VR, Ridker PM. Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy: More Than Meets the Plaque. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679526
  3. Groeneveld ME, van der Reijden JJ, Tangelder GJ et al. Peroxynitrite Footprint in Circulating Neutrophils of Abdominal Aortic Aneurysm Patients Is Lower in Statin than in Non-statin Users. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28712812
  4. Gehrke T, Scherzad A, Hackenberg S et al. Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro. International journal of oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28713941
  5. Kim SW, Kang HJ, Bae KY et al. Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. Progress in neuro-psychopharmacology & biological psychiatry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689006

Ethnicity

  1. Mortensen MB, Falk E, Schmidt M. Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28698192
  2. Lin HF, Liao KF, Chang CM et al. Statin use correlates with reduced risk of chronic osteomyelitis: a nationwide case-control study in Taiwan. Current medical research and opinion 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28699801
  3. Zhao W, Zheng XL, Jiang ZN et al. Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689987
  4. Tomlinson B, Chan P, Liu ZM. Statin Responses in Chinese Patients. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740057 

FH

  1. Skoumas I, Ioakeimidis N, Vlachopoulos C et al. Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up. Angiology 2017:3319717718331. http://www.ncbi.nlm.nih.gov/pubmed/?term=28681648
  2. Nakamura M, Uno K, Hirayama A et al. Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. BMJ Open 2017; 7:e014427. http://www.ncbi.nlm.nih.gov/pubmed/?term=28674132
  3. Lasam G, Shambhu S, Fishberg R. Heterozygous Familial Hypercholesterolemia With APOE Haplotype: A Prospective Harbinger of a Catastrophic Cardiovascular Event. Cardiology research 2017; 8:117-122. http://www.ncbi.nlm.nih.gov/pubmed/?term=28725328
  4. Zafrir B, Jubran A, Lavie G et al. Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28701632
  5. Vuorio A, Kuoppala J, Kovanen PT et al. Statins for children with familial hypercholesterolemia. The Cochrane database of systematic reviews 2017; 7:Cd006401. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685504
  6. Choi J, Khan AM, Jarmin M et al. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. Lipids Health Dis 2017; 16:141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28738813
  7. Ershova AI, Meshkov AN, Bazhan SS et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoS One 2017; 12:e0181148. http://www.ncbi.nlm.nih.gov/pubmed/?term=28719663
  8. Climent E, Perez-Calahorra S, Marco-Benedi V et al. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific reports 2017; 7:5596. http://www.ncbi.nlm.nih.gov/pubmed/?term=28717233
  9. Jetty V, Glueck CJ, Lee K et al. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol >/=70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. Vasc Health Risk Manag 2017; 13:247-253. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740397

Generics

  1. Loch A, Bewersdorf JP, Kofink D et al. Generic atorvastatin is as effective as the brand-name drug (LIPITOR(R)) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC research notes 2017; 10:291. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716156

Genetics

  1. Cunha V, Santos MM, Moradas-Ferreira P et al. Simvastatin modulates gene expression of key receptors in zebrafish embryos. Journal of toxicology and environmental health. Part A 2017:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28682217
  2. Maxwell WD, Ramsey LB, Johnson SG et al. Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672099

Guidelines

  1. Stulc T, Lanska V, Snejdrlova M et al. A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. Archives of medical science : AMS 2017; 13:705-710. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721135
  2. Cesena FHY, Laurinavicius AG, Valente VA et al. Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. Arquivos brasileiros de cardiologia 2017; 108:508-517. http://www.ncbi.nlm.nih.gov/pubmed/?term=28699974
  3. Heller DJ, Coxson PG, Penko J et al. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28687710
  4. Shehab A, Al-Rasadi K, Arafah M et al. The management of dyslipidaemia in patients with type 2 diabetes mellitus receiving lipid-lowering drugs: a sub-analysis of the CEPHEUS findings. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28677510
  5. Vlachopoulos C, Andrikopoulos G, Terentes-Printzios D et al. Patients with acute coronary syndrome are at high risk prior to the event and lipid management is underachieved pre- and post-hospitalization. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676022
  6. Bertoluci MC, Moreira RO, Faludi A et al. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetology & metabolic syndrome 2017; 9:53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28725272
  7. Gulizia MM, Colivicchi F, Arca M et al. ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. European heart journal supplements : journal of the European Society of Cardiology 2017; 19:D55-d63. http://www.ncbi.nlm.nih.gov/pubmed/?term=28751834
  8. Akhabue E, Rittner SS, Carroll JE et al. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28673901
  9. Wander GS, Jadhav UM, Chemburkar A et al. Lipid management in India: a nationwide, cross-sectional physician survey. Lipids Health Dis 2017; 16:130. http://www.ncbi.nlm.nih.gov/pubmed/?term=28673294

LDL- related parameters

  1. Vlachopoulos C, Andrikopoulos G, Terentes-Printzios D et al. Patients with acute coronary syndrome are at high risk prior to the event and lipid management is underachieved pre- and post-hospitalization. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676022
  2. Lawler PR, Akinkuolie AO, Chu AY et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28733430
  3. Maxwell WD, Ramsey LB, Johnson SG et al. Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672099
  4. Raghow R. Statins redux: A re-assessment of how statins lower plasma cholesterol. World J Diabetes 2017; 8:230-234. http://www.ncbi.nlm.nih.gov/pubmed/?term=28694924

Lifestyle

  1. Shaya GE, Juraschek SP, Feldman DI et al. Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716336
  2. Khan TM, Iqbal S, Rashid MA. Comparison Of Lipid Lowering Effect Of Extra Virgin Olive Oil And Atorvastatin In Dyslipidaemia In Type 2 Diabetes Mellitus. Journal of Ayub Medical College, Abbottabad : JAMC 2017; 29:83-86. http://www.ncbi.nlm.nih.gov/pubmed/?term=28712181

Meta-analyses

  1. Bazoukis G, Papadatos SS, Letsas KP et al. Impact of statin therapy on all-cause mortality and ICD interventions in heart failure patients - a systematic review. Acta Cardiol 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685653
  2. Peng D, Fong A, Pelt AV. Original Research: The Effects of Red Yeast Rice Supplementation on Cholesterol Levels in Adults. The American journal of nursing 2017; 117:46-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=28749884
  3. Awad K, Mikhailidis DP, Toth PP et al. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28741244
  4. Vuorio A, Kuoppala J, Kovanen PT et al. Statins for children with familial hypercholesterolemia. The Cochrane database of systematic reviews 2017; 7:Cd006401. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685504
  5. Squizzato A, Suter MB, Nerone M et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Internal and emergency medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28695455
  6. Farnier M, Colhoun HM, Sasiela WJ et al. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28693998
  7. Thomas T, Loke Y, Beales ILP. Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma. Journal of gastrointestinal cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28691139
  8. Liang M, Yang S, Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials. Medicine (Baltimore) 2017; 96:e7384. http://www.ncbi.nlm.nih.gov/pubmed/?term=28682890
  9. Xie W, Zhu Q, Liu Q et al. Statin use and endometrial cancer risk: a meta-analysis. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711915
  10. Venegas Sanabria LC, Barbosa Balaquera S, Suarez Acosta AM et al. [Statin and risk of falls in the elderly: A sytematic review of the literature]. Revista espanola de geriatria y gerontologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28728682

Metabolic Syndrome - Diabetes

  1. Shehab A, Al-Rasadi K, Arafah M et al. The management of dyslipidaemia in patients with type 2 diabetes mellitus receiving lipid-lowering drugs: a sub-analysis of the CEPHEUS findings. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28677510
  2. Wilbek TE, Jansen RB, Jorgensen B, Svendsen OL. Risk Factors for Premature Death in Diabetes Patients who Undergo Amputations below Ankle Level. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28675915
  3. Chen W, Tian T, Wang S et al. The characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course and the intervention by statins in the very elderly patients. Journal of diabetes investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685957
  4. Elnaem MH, Mohamed MHN, Huri HZ et al. Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges. J Pharm Bioallied Sci 2017; 9:80-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28717329
  5. Nunley KA, Orchard TJ, Ryan CM et al. Statin use and cognitive function in middle-aged adults with type 1 diabetes. World J Diabetes 2017; 8:286-296. http://www.ncbi.nlm.nih.gov/pubmed/?term=28694929

New Treatments

  1. El Shahawy M, Cannon CP, Blom DJ et al. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750828
  2. Peng D, Fong A, Pelt AV. Original Research: The Effects of Red Yeast Rice Supplementation on Cholesterol Levels in Adults. The American journal of nursing 2017; 117:46-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=28749884
  3. Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Archives of medical science : AMS 2017; 13:914-929. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721159
  4. Thomas T, Zhou H, Karmally W et al. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28729361
  5. Koh KK. Letter by Koh Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". Circulation 2017; 136:118-119. http://www.ncbi.nlm.nih.gov/pubmed/?term=28674099
  6. Watts GF, Chan DC, Somaratne R et al. Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". Circulation 2017; 136:120-121. http://www.ncbi.nlm.nih.gov/pubmed/?term=28674100
  7. Page MM, Watts GF. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28736830
  8. Dixon DL, Buckley LF, Trankle CR et al. Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug design, development and therapy 2017; 11:2121-2129. http://www.ncbi.nlm.nih.gov/pubmed/?term=28744103
  9. Casula M, Pirillo A, Norata GD, Catapano AL. PCSK9 inhibition in statin-intolerant HeFH patients: What's new? Eur J Prev Cardiol 2017:2047487317721980. http://www.ncbi.nlm.nih.gov/pubmed/?term=28728483
  10. Squizzato A, Suter MB, Nerone M et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Internal and emergency medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28695455
  11. Farnier M, Colhoun HM, Sasiela WJ et al. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28693998
  12. Alaarg A, Senders ML, Varela-Moreira A et al. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J Control Release 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28700897
  13. Choi J, Khan AM, Jarmin M et al. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. Lipids Health Dis 2017; 16:141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28738813
  14. Jetty V, Glueck CJ, Lee K et al. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol >/=70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. Vasc Health Risk Manag 2017; 13:247-253. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740397
  15. Murin J. [What has the GLAGOV clinical study shown?]. Vnitr Lek 2017; 63:329-332. http://www.ncbi.nlm.nih.gov/pubmed/?term=28726431 

PAD and statins

  1. Foley R, Singh GD, Kokkinidis DG et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711864

Pleiotropic effects of statins

  1. Bazoukis G, Papadatos SS, Letsas KP et al. Impact of statin therapy on all-cause mortality and ICD interventions in heart failure patients - a systematic review. Acta Cardiol 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685653
  2. Ghanim H, Green K, Abuaysheh S et al. Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. Atherosclerosis 2017; 263:278-286. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711708
  3. Stokkeland K, Lageborn CT, Ekbom A et al. Statins and ACE Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28691216
  4. Kaviani E, Rahmani M, Kaeidi A et al. Protective Effect of Atorvastatin on D-galactose-Induced Aging Model in Mice. Behavioural brain research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750834
  5. Aouba A. KRASG12D, pulmonary LCH, and atorvastatin. Blood 2017; 130:391-392. http://www.ncbi.nlm.nih.gov/pubmed/?term=28751357
  6. Kwon O, Kang SJ, Kang SH et al. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679524
  7. Taqueti VR, Ridker PM. Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy: More Than Meets the Plaque. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679526
  8. Eilenberg W, Stojkovic S, Kaider A et al. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672747
  9. Lin HF, Liao KF, Chang CM et al. Statin use correlates with reduced risk of chronic osteomyelitis: a nationwide case-control study in Taiwan. Current medical research and opinion 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28699801
  10. Fracassi A, Marangoni M, Rosso P et al. Statins and the brain: more than lipid lowering agents? Curr Neuropharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676012
  11. Athyros VG, Boutari C, Stavropoulos K et al. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676019
  12. Mitsiou E, Boutari C, Kotsis V et al. Effect of low (5 mg) vs high (20-40 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28669329
  13. Papademetriou M, Athyros VG, Geladari E et al. The co-existence of NASH and chronic kidney disease boosts cardiovascular risk: are there any common therapeutic options? Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676027
  14. Xie Y, Tan X, Huang J et al. Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis. Drug delivery 2017; 24:1067-1076. http://www.ncbi.nlm.nih.gov/pubmed/?term=28705021
  15. Han E, Kim G, Lee JY et al. Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes. Endocrinol Metab (Seoul) 2017; 32:274-280. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685516
  16. Ghayour MB, Abdolmaleki A, Rassouli MB. Neuroprotective effect of Lovastatin on motor deficit induced by sciatic nerve crush in the rat. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28688913
  17. Kunutsor SK, Whitehouse MR, Blom AW, Laukkanen JA. Statins and venous thromboembolism: do they represent a viable therapeutic agent? Expert Rev Cardiovasc Ther 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28724320
  18. Suda G, Ito J, Nagasaka A et al. Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: a randomized controlled study. Hepatology research : the official journal of the Japan Society of Hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28722780
  19. Zhang X, Sun Y, Xie H et al. The effect of simvastatin on periprosthetic bone mineral density in the hypercholesterolaemic patients after total hip arthroplasty. Int Orthop 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28681228
  20. Moazen-Zadeh E, Shirzad F, Karkhaneh-Yousefi MA et al. Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of child and adolescent psychopharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28719227
  21. Al-Kuraishy HM, Al-Gareeb AI. Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins. Journal of laboratory physicians 2017; 9:163-169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706385
  22. Ranjan R, Patil SR, H RV. Effect of in-situ application of simvastatin gel in surgical management of osseous defects in chronic periodontitis-A randomized clinical trial. Journal of oral biology and craniofacial research 2017; 7:113-118. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706785
  23. Saifi AM, Giraddi GB, Ahmed N. Healing of extraction socket following local application of simvastatin: A split mouth prospective study. Journal of oral biology and craniofacial research 2017; 7:106-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706784
  24. Liang M, Yang S, Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials. Medicine (Baltimore) 2017; 96:e7384. http://www.ncbi.nlm.nih.gov/pubmed/?term=28682890
  25. Sequetto PL, Goncalves RV, Pinto AS et al. Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28743325
  26. Pu H, Zhang Q, Zhao C et al. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer. Pathology oncology research : POR 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28744693
  27. Jia S, Xie P, Hong SJ et al. Local Application of Statins Significantly Reduced Hypertrophic Scarring in a Rabbit Ear Model. Plastic and reconstructive surgery. Global open 2017; 5:e1294. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740761
  28. Carillion A, Feldman S, Na N et al. Atorvastatin reduces beta-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS One 2017; 12:e0180103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28727746
  29. Kim SW, Kang HJ, Bae KY et al. Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. Progress in neuro-psychopharmacology & biological psychiatry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689006
  30. Naeimi RA, Amiri FT, Khalatbary AR et al. Atorvastatin mitigates testicular injuries induced by ionizing radiation in mice. Reproductive toxicology (Elmsford, N.Y.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28668617
  31. Wu S, Yang R, Wang G. Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4+ CD25+ Foxp3+ T cells in an asthma mouse model. Scientific reports 2017; 7:6084. http://www.ncbi.nlm.nih.gov/pubmed/?term=28729731
  32. Shin SK, Cho JH, Kim EJ et al. Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model. World J Gastroenterol 2017; 23:4559-4568. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740344 

Primary Prevention

  1. Heller DJ, Coxson PG, Penko J et al. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28687710

Registry data

  1. Tentzeris I, Farhan S, Freynhofer MK et al. Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28734463
  2. Skoumas I, Ioakeimidis N, Vlachopoulos C et al. Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up. Angiology 2017:3319717718331. http://www.ncbi.nlm.nih.gov/pubmed/?term=28681648
  3. De Jong HJI, van Staa TP, Lalmohamed A et al. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. Ann Rheum Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28684558
  4. Oza A, Lu N, Schoenfeld SR et al. Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28698231
  5. Stokkeland K, Lageborn CT, Ekbom A et al. Statins and ACE Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28691216
  6. Ooba N, Setoguchi S, Sato T, Kubota K. Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening. BMJ Open 2017; 7:e015935. http://www.ncbi.nlm.nih.gov/pubmed/?term=28667223
  7. Shah Z, Masoomi R, Thapa R et al. Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study. Cerebrovasc Dis 2017; 44:150-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689200
  8. Lin HF, Liao KF, Chang CM et al. Statin use correlates with reduced risk of chronic osteomyelitis: a nationwide case-control study in Taiwan. Current medical research and opinion 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28699801
  9. Zhao W, Zheng XL, Jiang ZN et al. Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689987
  10. Foley R, Singh GD, Kokkinidis DG et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711864
  11. Park CH, Kang EW, Park JT et al. Association of serum lipid levels over time with survival in incident peritoneal dialysis patients. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28669685
  12. Pursnani A, Massaro JM, D'Agostino RB, Sr. et al. Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017:Jco2016713594. http://www.ncbi.nlm.nih.gov/pubmed/?term=28700275
  13. Thomas T, Loke Y, Beales ILP. Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma. Journal of gastrointestinal cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28691139
  14. Wander GS, Jadhav UM, Chemburkar A et al. Lipid management in India: a nationwide, cross-sectional physician survey. Lipids Health Dis 2017; 16:130. http://www.ncbi.nlm.nih.gov/pubmed/?term=28673294
  15. Sung PH, Chiang HJ, Lee MS et al. Combined renin-angiotensin-aldosterone system blockade and statin therapy effectively reduces the risk of cerebrovascular accident in autosomal dominant polycystic kidney disease: a nationwide population-based cohort study. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711910
  16. Raebel MA, Dyer W, Nichols GA et al. Relationships Between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients With Diabetes. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28752555
  17. Parkin L, Sharples KJ, Barson DJ, Blank ML. Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study. PLoS One 2017; 12:e0182066. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753656
  18. Climent E, Perez-Calahorra S, Marco-Benedi V et al. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific reports 2017; 7:5596. http://www.ncbi.nlm.nih.gov/pubmed/?term=28717233
  19. Nunley KA, Orchard TJ, Ryan CM et al. Statin use and cognitive function in middle-aged adults with type 1 diabetes. World J Diabetes 2017; 8:286-296. http://www.ncbi.nlm.nih.gov/pubmed/?term=28694929
  20. Zheng F, Guo Y, Krischek B. Statin Use in Patients with Aneurysmal Subarachnoid Hemorrhage May not Significantly Reduce the Occurrence of Delayed Ischemic Neurological Deficit. World neurosurgery 2017; 104:1032-1033. http://www.ncbi.nlm.nih.gov/pubmed/?term=28732423

Renal Disease

  1. Park CH, Kang EW, Park JT et al. Association of serum lipid levels over time with survival in incident peritoneal dialysis patients. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28669685
  2. Syed MH, Khandelwal PN, Thawani VR, Katare SS. Efficacy of Atorvastatin in Prevention of Contrast-induced Nephropathy in High-risk Patients Undergoing Angiography: A Double-blind Randomized Controlled Trial. Journal of pharmacology & pharmacotherapeutics 2017; 8:50-53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706398
  3. Bei WJ, Chen SQ, Li HL et al. Comparing common doses (double-dose vs usual-dose) of atorvastatin for preventing contrast-induced acute kidney injury and mortality after coronary angiography. Medicine (Baltimore) 2017; 96:e7501. http://www.ncbi.nlm.nih.gov/pubmed/?term=28746193
  4. Sung PH, Chiang HJ, Lee MS et al. Combined renin-angiotensin-aldosterone system blockade and statin therapy effectively reduces the risk of cerebrovascular accident in autosomal dominant polycystic kidney disease: a nationwide population-based cohort study. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711910
  5. Parkin L, Sharples KJ, Barson DJ, Blank ML. Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study. PLoS One 2017; 12:e0182066. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753656

Reviews

  1. Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Archives of medical science : AMS 2017; 13:914-929. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721159
  2. Athyros VG, Boutari C, Stavropoulos K et al. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676019
  3. Papademetriou M, Athyros VG, Geladari E et al. The co-existence of NASH and chronic kidney disease boosts cardiovascular risk: are there any common therapeutic options? Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676027
  4. Page MM, Watts GF. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28736830
  5. Dixon DL, Buckley LF, Trankle CR et al. Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug design, development and therapy 2017; 11:2121-2129. http://www.ncbi.nlm.nih.gov/pubmed/?term=28744103
  6. Casula M, Pirillo A, Norata GD, Catapano AL. PCSK9 inhibition in statin-intolerant HeFH patients: What's new? Eur J Prev Cardiol 2017:2047487317721980. http://www.ncbi.nlm.nih.gov/pubmed/?term=28728483
  7. Kunutsor SK, Whitehouse MR, Blom AW, Laukkanen JA. Statins and venous thromboembolism: do they represent a viable therapeutic agent? Expert Rev Cardiovasc Ther 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28724320
  8. Mascitelli L, Goldstein MR. Statin Intolerance and the Obsession With Aggressive Cholesterol Lowering to Prevent Coronary Heart Disease. J Am Coll Cardiol 2017; 70:684. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750707
  9. Tomlinson B, Chan P, Liu ZM. Statin Responses in Chinese Patients. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28740057
  10. Elnaem MH, Mohamed MHN, Huri HZ et al. Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges. J Pharm Bioallied Sci 2017; 9:80-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28717329
  11. Maxwell WD, Ramsey LB, Johnson SG et al. Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672099
  12. Vaclavik J. [News in the treatment of hypertension and dyslipidemia]. Vnitr Lek 2017; 63:333-337. http://www.ncbi.nlm.nih.gov/pubmed/?term=28726432

Safety and side effects

  1. Mukai Y, Narita M, Akiyama E et al. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants. Biological & pharmaceutical bulletin 2017; 40:1078-1085. http://www.ncbi.nlm.nih.gov/pubmed/?term=28674251
  2. Ooba N, Setoguchi S, Sato T, Kubota K. Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening. BMJ Open 2017; 7:e015935. http://www.ncbi.nlm.nih.gov/pubmed/?term=28667223
  3. Tanner RM, Safford MM, Monda KL et al. Primary Care Physician Perspectives on Barriers to Statin Treatment. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28710589
  4. Capogrosso Sansone A, Convertino I, Galiulo MT et al. Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database. Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28681266
  5. Gulizia MM, Colivicchi F, Arca M et al. ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. European heart journal supplements : journal of the European Society of Cardiology 2017; 19:D55-d63. http://www.ncbi.nlm.nih.gov/pubmed/?term=28751834
  6. Stopfer P, Giessmann T, Hohl K et al. Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. European journal of drug metabolism and pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685495
  7. Casula M, Pirillo A, Norata GD, Catapano AL. PCSK9 inhibition in statin-intolerant HeFH patients: What's new? Eur J Prev Cardiol 2017:2047487317721980. http://www.ncbi.nlm.nih.gov/pubmed/?term=28728483
  8. Manoj K, Jain N, Madhu SV. Myopathy in Patients Taking Atorvastatin: A Pilot Study. Indian journal of endocrinology and metabolism 2017; 21:504-509. http://www.ncbi.nlm.nih.gov/pubmed/?term=28670530
  9. Mascitelli L, Goldstein MR. Statin Intolerance and the Obsession With Aggressive Cholesterol Lowering to Prevent Coronary Heart Disease. J Am Coll Cardiol 2017; 70:684. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750707
  10. Serban MC, Muntner P, Rosenson RS. Reply: Statin Intolerance and Risk for Recurrent Myocardial Infarction, Coronary Heart Disease Events, and All-Cause Mortality. J Am Coll Cardiol 2017; 70:685-686. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750708
  11. Selim A, Khalaf MM, Gad AM, Abd El-Raouf OM. Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin-induced renal injury in rats. Journal of biochemical and molecular toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28683192
  12. Buttar RS, Batra J, Kreimerman J et al. Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels. Journal of general internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28707259
  13. Obayashi H, Kobayashi N, Nezu Y et al. Plasma 2-hydroxyglutarate and hexanoylcarnitine levels are potential biomarkers for skeletal muscle toxicity in male Fischer 344 rats. The Journal of toxicological sciences 2017; 42:385-396. http://www.ncbi.nlm.nih.gov/pubmed/?term=28717097
  14. El Mekki AB, Chaib A. [Drug induced angioedema: a rare side effect of simvastatin]. The Pan African medical journal 2017; 26:213. http://www.ncbi.nlm.nih.gov/pubmed/?term=28690728
  15. Kriegbaum M, Liisberg KB, Wallach-Kildemoes H. Pattern of statin use changes following media coverage of its side effects. Patient preference and adherence 2017; 11:1151-1157. http://www.ncbi.nlm.nih.gov/pubmed/?term=28744105
  16. Maxwell WD, Ramsey LB, Johnson SG et al. Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672099
  17. Parkin L, Sharples KJ, Barson DJ, Blank ML. Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study. PLoS One 2017; 12:e0182066. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753656
  18. Leite GAA, Figueiredo TM, Sanabria M et al. Ascorbic acid supplementation partially prevents the delayed reproductive development in juvenile male rats exposed to rosuvastatin since prepuberty. Reproductive toxicology (Elmsford, N.Y.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28729172
  19. Venegas Sanabria LC, Barbosa Balaquera S, Suarez Acosta AM et al. [Statin and risk of falls in the elderly: A sytematic review of the literature]. Revista espanola de geriatria y gerontologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28728682
  20. Climent E, Perez-Calahorra S, Marco-Benedi V et al. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific reports 2017; 7:5596. http://www.ncbi.nlm.nih.gov/pubmed/?term=28717233
  21. Sharma N, Cooper R, Kuh D. Associations of statin use with motor performance and myalgia may be modified by 25-hydroxyvitamin D: findings from a British birth cohort. Scientific reports 2017; 7:6578. http://www.ncbi.nlm.nih.gov/pubmed/?term=28747665
  22. Navratilova L, Mandikova JR, Pavek P et al. Honey flavonoids inhibit hOATP2B1 and hOATP1A2 transporters and hOATP-mediated rosuvastatin cell uptake in vitro. Xenobiotica 2017:1-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=28745105

Stroke and CNS

  1. Shah Z, Masoomi R, Thapa R et al. Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study. Cerebrovasc Dis 2017; 44:150-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=28689200
  2. Eilenberg W, Stojkovic S, Kaider A et al. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672747
  3. Fracassi A, Marangoni M, Rosso P et al. Statins and the brain: more than lipid lowering agents? Curr Neuropharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28676012
  4. Florentin M, Elisaf MS. Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke. Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28695474
  5. Wang Y, Geng Y, Shi Z et al. Good recovery of subarachnoid hemorrhage concomitant with ischemia due to anterior cerebral artery dissection by conservative treatment: A case report. Experimental and therapeutic medicine 2017; 14:155-158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28672907
  6. Farzanegan GR, Derakhshan N, Khalili H et al. Effects of atorvastatin on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury; a randomized double-blind placebo-controlled clinical trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28688622
  7. Sung PH, Chiang HJ, Lee MS et al. Combined renin-angiotensin-aldosterone system blockade and statin therapy effectively reduces the risk of cerebrovascular accident in autosomal dominant polycystic kidney disease: a nationwide population-based cohort study. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711910
  8. Nunley KA, Orchard TJ, Ryan CM et al. Statin use and cognitive function in middle-aged adults with type 1 diabetes. World J Diabetes 2017; 8:286-296. http://www.ncbi.nlm.nih.gov/pubmed/?term=28694929
  9. Zheng F, Guo Y, Krischek B. Statin Use in Patients with Aneurysmal Subarachnoid Hemorrhage May not Significantly Reduce the Occurrence of Delayed Ischemic Neurological Deficit. World neurosurgery 2017; 104:1032-1033. http://www.ncbi.nlm.nih.gov/pubmed/?term=28732423 

Triglycerides/HDL

  1. Pirillo A, Catapano AL. Pitavastatin and HDL: Effects on plasma levels and function(s). Atherosclerosis. Supplements 2017; 27:e1-e9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716185 

Trials

  1. Tvaryanas AP, Mahaney HJ, Schroeder VM, Maupin GM. Statin Therapy in Low-Risk Air Force Aviators with Isolated Hypercholesterolemia. Aerosp Med Hum Perform 2017; 88:752-759. http://www.ncbi.nlm.nih.gov/pubmed/?term=28720185
  2. El Shahawy M, Cannon CP, Blom DJ et al. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28750828
  3. Kabaklic A, Fras Z. Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram: a pilot study. Archives of medical science : AMS 2017; 13:827-836. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721151
  4. Stulc T, Lanska V, Snejdrlova M et al. A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. Archives of medical science : AMS 2017; 13:705-710. http://www.ncbi.nlm.nih.gov/pubmed/?term=28721135
  5. Thomas T, Zhou H, Karmally W et al. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28729361
  6. Pirillo A, Catapano AL. Pitavastatin and HDL: Effects on plasma levels and function(s). Atherosclerosis. Supplements 2017; 27:e1-e9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716185
  7. Ghanim H, Green K, Abuaysheh S et al. Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. Atherosclerosis 2017; 263:278-286. http://www.ncbi.nlm.nih.gov/pubmed/?term=28711708
  8. Loch A, Bewersdorf JP, Kofink D et al. Generic atorvastatin is as effective as the brand-name drug (LIPITOR(R)) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC research notes 2017; 10:291. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716156
  9. Nakamura M, Uno K, Hirayama A et al. Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. BMJ Open 2017; 7:e014427. http://www.ncbi.nlm.nih.gov/pubmed/?term=28674132
  10. Smith A, Murphy L, Zgaga L et al. Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer. Br J Cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28720842
  11. Tanner RM, Safford MM, Monda KL et al. Primary Care Physician Perspectives on Barriers to Statin Treatment. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28710589
  12. Kwon O, Kang SJ, Kang SH et al. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679524
  13. Taqueti VR, Ridker PM. Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy: More Than Meets the Plaque. Circulation. Cardiovascular imaging 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28679526
  14. Mitsiou E, Boutari C, Kotsis V et al. Effect of low (5 mg) vs high (20-40 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28669329
  15. Han E, Kim G, Lee JY et al. Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes. Endocrinol Metab (Seoul) 2017; 32:274-280. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685516
  16. Almalki ZS, Guo JJ, Alahmari A et al. Cost-effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients with a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. Heart, lung & circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716519
  17. Suda G, Ito J, Nagasaka A et al. Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: a randomized controlled study. Hepatology research : the official journal of the Japan Society of Hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28722780
  18. Zhang L, Wahle A, Chen Z et al. Predicting Locations of High-Risk Plaques in Coronary Arteries in Patients Receiving Statin Therapy. IEEE transactions on medical imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28708548
  19. Manoj K, Jain N, Madhu SV. Myopathy in Patients Taking Atorvastatin: A Pilot Study. Indian journal of endocrinology and metabolism 2017; 21:504-509. http://www.ncbi.nlm.nih.gov/pubmed/?term=28670530
  20. Calza L, Magistrelli E, Colangeli V et al. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infectious diseases (London, England) 2017:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28683645
  21. Briguori C, Quintavalle C, D'Alessio F et al. Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28668399
  22. Zhang X, Sun Y, Xie H et al. The effect of simvastatin on periprosthetic bone mineral density in the hypercholesterolaemic patients after total hip arthroplasty. Int Orthop 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28681228
  23. Lawler PR, Akinkuolie AO, Chu AY et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28733430
  24. Farnier M, Colhoun HM, Sasiela WJ et al. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28693998
  25. Farzanegan GR, Derakhshan N, Khalili H et al. Effects of atorvastatin on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury; a randomized double-blind placebo-controlled clinical trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28688622
  26. Syed MH, Khandelwal PN, Thawani VR, Katare SS. Efficacy of Atorvastatin in Prevention of Contrast-induced Nephropathy in High-risk Patients Undergoing Angiography: A Double-blind Randomized Controlled Trial. Journal of pharmacology & pharmacotherapeutics 2017; 8:50-53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28706398
  27. Choi J, Khan AM, Jarmin M et al. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. Lipids Health Dis 2017; 16:141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28738813
  28. Im E, Cho YH, Suh Y et al. High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28716428

Women and elderly

  1. Chen W, Tian T, Wang S et al. The characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course and the intervention by statins in the very elderly patients. Journal of diabetes investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28685957
  2. Raebel MA, Dyer W, Nichols GA et al. Relationships Between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients With Diabetes. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28752555
 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.

Cancella iscrizione | Unsubscribe | Inviato con MailUp